FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1389-1393 November 4, 1993 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Light-chain amyloidosis and light-chain deposition disease are closely related processes characterized by tissue deposition of organized (fibrillar) or nonorganized material related to monoclonal immunoglobulin light chains. Both conditions can occur in patients with immunoproliferative disorders. The clinical manifestations of light-chain deposition disease result from multivisceral involvement and are heterogeneous. Rapidly progressive renal failure or the nephrotic syndrome is the most common manifestation, but heart failure, arrhythmia, liver involvement (peliosis), and neurologic disorders may also be present. These findings may be caused by structural abnormalities or unusual behavior of deposited light chains. In particular, pathogenic light chains are characterized by unusual . . . [Full Text of this Article]

Methods

Patients

Pathological Studies

Immunochemical Studies

Study of Messenger RNA in Patient 1

Results

Histopathological Studies

Immunochemical and Sequencing Studies of Serum and Urine

Discussion

Source Information

From the Laboratory of Immunology and Molecular Interactions (Centre National de la Recherche Scientifique Associated Research Unit 1172), University Hospital and Faculty of Sciences, Poitiers (P.A., A.A.K., M.C., J.-L.P.); the Department of Nephrology, University Hospital, Poitiers (G.T.); and the Department of Pathology (E.J.) and the Human and Experimental Digestive Cancer Unit (Institut National de la Sante et de la Recherche Medicale Unit 252) (B.C., F.M.), University Hospital, Dijon -- all in France.

Address reprint requests to Dr. Aucouturier at the Centre National de la Recherche Scientifique, Unite de Recherche Associee 1172, Centre Hospitalier Universitaire, B.P. 577, F-86021 Poitiers, France.

References

This article has been cited by other articles:

• Ronco, P., Plaisier, E., Mougenot, B., Aucouturier, P. (2006). Immunoglobulin Light (Heavy)-Chain Deposition Disease: From Molecular Medicine to Pathophysiology-Driven Therapy. CJASN 1: 1342-1350 [Abstract] [Full Text]  
• Merlini, G., Stone, M. J. (2006). Dangerous small B-cell clones. Blood 108: 2520-2530 [Abstract] [Full Text]  
• Komatsuda, A., Maki, N., Wakui, H., Ohtani, H., Hatakeyama, T., Yasuda, T., Nakamoto, Y., Imai, H., Sawada, K.-i. (2005). Development of systemic {lambda}-light chain amyloidosis in a patient with {gamma}-heavy chain deposition disease during long-term follow-up. Nephrol Dial Transplant 20: 434-437 [Full Text]  
• Vedder, A. C., Weening, J. J., Krediet, R. T. (2004). Intracapillary proliferative glomerulonephritis due to heavy chain deposition disease. Nephrol Dial Transplant 19: 1302-1304 [Full Text]  
• LIN, J., MARKOWITZ, G. S., VALERI, A. M., KAMBHAM, N., SHERMAN, W. H., APPEL, G. B., D'AGATI, V. D. (2001). Renal Monoclonal Immunoglobulin Deposition Disease: The Disease Spectrum. J. Am. Soc. Nephrol. 12: 1482-1492 [Abstract] [Full Text]  
• RONCO, P. M., ALYANAKIAN, M.-A., MOUGENOT, B., AUCOUTURIER, P. (2001). Light Chain Deposition Disease: A Model of Glomerulosclerosis Defined at the Molecular Level. J. Am. Soc. Nephrol. 12: 1558-1565 [Full Text]  
• MOULIN, B., DERET, S., MARIETTE, X., KOURILSKY, O., IMAI, H., DUPOUET, L., MARCELLIN, L., KOLB, I., AUCOUTURIER, P., BROUET, J.-C., RONCO, P. M., MOUGENOT, B. (1999). Nodular Glomerulosclerosis with Deposition of Monoclonal Immunoglobulin Heavy Chains Lacking CH1. J. Am. Soc. Nephrol. 10: 519-528 [Abstract] [Full Text]  
• Solomon, A., Weiss, D. T. (1993). Ominous Consequences of Immunoglobulin Deposition. NEJM 329: 1422-1423 [Full Text]